RxDoctor Payments Data

Thomas Gaines

Interventional Cardiology · Metairie, LANPI 1679731574

Payments from drug & device makers

$3,295in general payments, 2019–2025

Across 83 payments — averaging $39.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Abiomed$392
  • Amgen$333
  • Cardiovascular Systems Inc.$274
  • Edwards Lifesciences$170
  • Johnson & Johnson$124
  • plus $747 from 15 others

What the payments were for

  • Travel & lodging$1,15235%
  • Food & beverage$2,14365%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,295 in reported general payments places this provider in the 15th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$67,556
Repatha SureclickEvolocumab12$15,002
EntrestoSacubitril/Valsartan17$11,012
BrilintaTicagrelor11$6,580
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,532
Metoprolol Succinate151$1,062
Valsartan61$856
Cilostazol53$832
Bumetanide46$652
Flecainide Acetate20$641
Carvedilol115$577
Amlodipine-ValsartanAmlodipine Besylate/Valsartan11$552
Rosuvastatin Calcium101$487
Spironolactone102$420
Amlodipine Besylate92$415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$104$67,55680 claims
NovartisEntresto$91$11,01217 claims
AstraZenecaBrilinta$81$6,58011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →